FURAPREVIR
Chronic Hepatics C Virus (HCV) Genotype 1
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.Small moleculePhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Chronic Hepatics C Virus (HCV) Genotype 1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PARITAPREVIR Ain Shams University | Phase 3 | A |
OMBITASVIR Ain Shams University | Phase 3 | A |
Dasabuvir AbbVie | Phase 3 | A |
Ribavirin Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | Phase 4 | A |
Sofosbuvir Peking University First Hospital | Phase 4 | A |
View all 50 →
Same molecule, other indications
FURAPREVIR is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →